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ABSTRACT 
Objective: Ginger oleoresin (GO) plays an important role on the attenuation of complications associated to the cancer which is attributed to 6-
shogaol (6-SGL). The major challenge in using 6-SGL for therapeutic applications is its poor aqueous solubility, low stability in GI and low 
bioavailability. Considering the potent anticancer nature of 6-SGL and its synergistic activity with other constituents in GO, there is a need to 
develop a suitable drug delivery system.  
Methods: Thus in the present study, 6-SGL rich GO (6-SRGO) was incorporated into mixed micelles using phospholipid (Soya Lecithin) as a carrier. 
The prepared 6-SRGO loaded mixed micelles (6-SRGO-LMM) were characterized physically and chemically using Fourier transform infrared 
spectroscopy (FTIR), Differential scanning calorimetry (DSC) and further evaluated for stability study, in vitro release study, in vitro cytotoxicity 
study and in vivo anticancer activity in comparison with 6-SRGO.  
Results: The composition such as, drug content (86.27±1.56), encapsulation efficiency (81.55±1.05) and particle size (356.11±4.07) were optimized 
using 32
Conclusion: We have developed and investigated mixed micelles composed of phospholipids (soya lecithin S80) and SCH as an effective 
nanocarrier for the delivery of a natural lipophilic anticancer bioactive 6-SGL from 6-SRGO. 
 factorial design. FTIR and DSC study confirm that the 6-SGL from 6-SRGO was entrapped in the core of phospholipid by self-assembly 
method to form mixed micelles. The 6-SRGO-LMM exhibited significant in vitro (GI50-23.2 μg/ml) and in vivo anticancer activity in comparison with 
6-SRGO. 
Keywords: 6-shogaol, Mixed micelles, Factorial designs, Breast cancer 




Now a day’s natural dietary foods including vegetables, fruits, and 
spices aliments have been achieved a great attraction from the 
scientist of various healthcare departments, food industries and the 
normal public because of their safety, efficacy and availability at the 
comparatively lower price. In addition, they are believed to have no or 
very less toxic effects than the synthetic drugs [1, 2]. However, the low 
aqueous solubility, poor bioavailability, and the stability of 
phytoconstituents lead to hamper their use in the treatment of various 
diseases. Therefore, the various delivery system including 
nanotechnological-based drug-delivery systems has been designed for 
different naturally occuring phytoconstituents to increase the aqueous 
solubility and bio-availability and reduce the dose without hampering 
the efficacy of the drug, safety and the compatibility with patients [3]. 
6-shogaol rich ginger oleoresin (6-SRGO) is an oleoresin isolated 
from Zingiber officinale Rosc., consisting of higher content of 
phenolic ketones; gingerols and shogaols [4-6]. Traditionally they 
are used for the treatment of a cough, stomach upset, inflammation, 
hair diseases [7], diarrhoea, nausea and vomiting. Among the 
various phenolic constituents of ginger oleoresin (GO), the analogs 
of shogaols and gingerols have been known for their potent 
antioxidant, anti-inflammatory [8], antimicrobial [9] and anticancer 
activities [10]. Various studies have discovered that 6-shogaol (6-
SGL) possesses most potent anticancer activity than the other 
analogs of shogaols and gingerols [11]. Various in vitro studies have 
been demonstrated the role of 6-SGL in suppressing the different 
cancer cells like ovary [12], lungs, colon, gastrointestinal tract and 
neuroblastoma. The metabolites of 6-SGL are also known to possess 
anticancer activity [2, 13].  
The major challenge of using 6-SGL is its poor aqueous solubility; 
which limits its therapeutic efficacy [10-14]. Besides the high dose of 
6-SRGO is required to reach the therapeutic efficacy, which may lead 
to the several side effects such as diarrhea, nausea and many times 
the tolerance of the 6-SRGO. There are few attempts have been made 
to develop nanoformulations using a conventional extract of ginger 
but detail investigation, characterization and anticancer potential 
are not reported [15-19]. To overcome these problems present 
research aims at incorporating 6-SRGO within polymers to develop a 
drug delivery system displaying enhanced drug solubility, while 
reducing systemic toxicity of 6-SRGO.  
Mixed micelles; a system for the solubilisation of water-insoluble drugs 
to increase its efficacy [20, 21] is known for its stability and its ability to 
solubilize maximum amount of water-insoluble drugs in their inner core 
[22]. Mixed micelles are smaller in size and having outer hydrophilic 
shell which is responsible for prolonged circulation times in vivo and 
results in accumulation in the tumoral tissues. Mixed micelles also play 
an important role in pharmacokinetic and biodistribution behaviour of 
the drugs [23]. In addition, mixed micelles of 10–400 nm are 
advantageous for passive targeting into solid tumors by virtue of the 
enhanced permeability and retention (EPR) effect [24]. Such systems 
have been applied for delivery of various anticancer drugs such as 
doxorubicin, propofol, docetaxel and gambogic acid [25-29].  
To the best of our knowledge, no previous studies have attempted 
the preparation of 6-SRGO-loaded mixed micelles (LMM) to improve 
its anticancer efficacy. Therefore, this study was attempted to 
investigate the potentials of 6-shogaol rich ginger oleoresin-loaded 
mixed micelles (6-SRGO-LMM), to enhance solubility, physiological 
stability and anticancer efficiency.  
MATERIALS AND METHODS 
Materials 
Mixed micelles were produced using a carrier Phospholipid that was 
supplied by Cologne, Germany, with a melting point at 100 °C. The 
reference standard (pure isolated) of 6-shogaol (>96% purity w/w) 
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was purchased from Natural Remedies Pvt. Ltd. Bangalore, Karnataka, 
India. 6-SRGO was purchased from Nisarg Biotech, Satara, 
Maharashtra, India, which is totally free from any endotoxins. Dialysis 
bags (MW cut-off 12,000) were purchased from Sigma-Aldrich 
Chemical Private Ltd (Bangalore, India). The needed chemicals and 
reagents (analytical grade) used in this research work are purchased 
from Merck Specialties Private Limited, Mumbai, India. 
Quantification of 6-SGL present in GO 
6-shogaol present in ginger oleoresin was quantified using an RP-
HPLC method which was reported in our earlier study [30]. 
Preparation of 6-SRGO-LMM 
6-SRGO-LMM was prepared according to self-assembly method [31]. 
Extraction of 6-SGL was performed by adding the GO to a 
dehydrated ethanol containing a specific amount of phospholipid 
followed by mixing with a suitable quantity of sodium cholate 
hydrated (SCH) under stirring at room temperature. Sufficient 
distilled water was added under magnetic stirring at 2000 rpm for 
45 min followed by sonication for 10 min to obtain 10 ml of the 
mixed micellar suspension. Blank mixed micelles (devoid of 6-SRGO) 
were prepared in a similar manner. 
Optimization of 6-SRGO-LMM by 32
3
 factorial designs 
2
Characterization of 6-SRGO-LMM 
 factorial designs were adopted to optimize the micelle 
composition while studying the effect of phospholipid and SCH 
(independent variables) on Drug Content (DC), Entrapment 
Efficiency (EE) and Particle Size (PS) (three dependent variables or 
responses) by obtaining a response surface plot. 
Micelles size distribution and zeta potential 
The laser diffraction technique was used to determine the size of 
blank and 6-SRGO-LMM (Malvern 2000 SM; Malvern Instruments, 
Malvern, UK). The laser Doppler electrophoretic mobility 
measurements (Zetasizer 3000, Malvern Instruments) were done to 
measure the zeta potential at 25 °C. 
DC and EE 
The concentration of 6-SGL in the mixed micelles was determined by 
rapid and sensitive RP-HPLC method. The superficial 6-SGL was 
determined by washing 6-SRGO-LMM with ethanol and measuring the 
6-SGL content collected in the washing solution. EE was determined as 
the ratio between the encapsulated 6-SGL (total — superficial) and the 
feeding 6-SGL. The DC was determined as the ratio between the 
micelles collected at the end of the process and the mass of carrier 
added to 6-SRGO used in the preparation of micelles. 
Physical characterization 
Fourier transform infrared spectroscopy (FTIR) 
The pure 6-SRGO and 6-SRGO-LMM were characterized by FTIR 
spectroscopy in the 4000 to 400 cm−1 region using FTIR Spectro-
photometer (Jasco 4100). 
Differential scanning calorimetry (DSC) 
DSC was done to perform the thermal analysis of 6-SRGO and 6-SRGO-
LMM by using DSC 821, Mettler Toledo instrument. Near about 5 mg of 
6-SRGO-LMM were heated in a hermetically sealed aluminium pan 
with heating rate 10 °C per min under a nitrogen atmosphere (flow 
rate 50 ml/min). 6-SRGO was also analyzed for comparison. 
Surface morphology 
The morphology of 6-SRGO-LMM was performed using transmission 
electron microscopy (TEM). The sample preparation for the TEM 
was performed following the method reported in [3].  
Evaluation of 6-SRGO-LMM stability 
6-SRGO-LMM were transferred in glass containers and stored at 25 °C, 
protected from the light for 90 d to evaluate short-term stability 
studies. Micelles were evaluated with respect to the amount of 6-
SGL, PS and EE. 
In vitro release of 6-SRGO-LMM 
The in vitro release of 6-SRGO-LMM was carried out in 0.1N HCL (pH 
1.2) and in phosphate-buffer (pH 7.4) using dialysis bag diffusion 
technique [3]. A formulation equivalent to 1 mg of 6-SRGO or 1 mg 
6-SRGO solution (1 mg/ml in 50% w/w mixture of PEG 400 and 
water) as control was incorporated into a dialysis bag (cellulose 
membrane, MW cut-off 12,000 Da), sealed and incorporated into 50 
ml of release medium. The temperature of the entire system was 
maintained at 37±0.5 °C with constant magnetic stirring at 100 
rpm/min. At previously planned time intervals, the sample was 
removed and replaced with an equal volume of fresh medium in 
order to maintain sink conditions. 6-SGL present in the solution was 
quantified by using rapid and sensitive RP-HPLC method. Analysis of 
data was performed using PCP Disso software (V3; Poona College of 
Pharmacy, Pune, India). 
In vitro cytotoxicity study 
In vitro cytotoxicity study of free 6-SRGO, blank mixed micelles and 
6-SRGO-LMM were evaluated against human breast cancer MCF-7 
using in vitro SRB assay at Advanced Centre for Treatment, Research 
and Education in Cancer (ACTREC), Mumbai. The results of MCF-7 
were compared with that of marketed Adriamycin (Doxorubicin). 
The cytotoxicity protocol for SRB assay was followed by the method 
described by [3]. 
Acute toxicity study 
The acute toxicity study was performed for 6-SRGO and 6-SRGO-
LMM on swiss albino mice. The animals were randomly divided into 
eleven groups (n=6). The first group (control group) received feed 
and distilled water orally. Groups 2–6 were orally treated with 6-
SRGO with doses 55 mg/kg, 175 mg/kg, 550 mg/kg, 1750 mg/kg 
and 2000 mg/kg body weight, respectively. Groups 7–11 were orally 
treated with 6-SRGO-LMM with doses 55 mg/kg, 175 mg/kg, 550 
mg/kg, 1750 mg/kg and 2000 mg/kg body weight, respectively. The 
animals were continuously observed for general behavioural 
changes, a sign of toxicity, and mortality for 1 h after treatment and 
then intermittently for 4 h and thereafter over a period of 24 h. Mice 
were further observed for up to 14 d for behavioural change and 
sign of toxicity. 
In vivo anticancer activity of 6-SRGO and 6-SRGO-LMM against 
Dalton’s Ascitic Lymphoma (DAL) in mice 
Male Swiss albino mice having the weight range of 20 gm to 25 gm 
were used for the study. They were kept in to micro nylon boxes at 
control temperature (temp 25±2 °C). The experimental protocol was 
approved by the Institutional Animal Ethics Committee (IAEC) 
constituted in accordance with the rules and guidelines of the 
Committee for the Purpose of Control and Supervision on 
Experimental Animals (CPCSEA), India (Approved protocol no-
CPCSEA/Q. A./01/2014-15; institutional approval no-CPCSEA/ 
1999/100). 
Induction of cancer cells 
DLA cells were procured from Amala cancer research center, 
Trissur, Kerala, India. The cancer cells were implanted in vivo in 
mice by intraperitoneal route. Before transferring the cancerous 
cells to mice, by using saline solution the DLA cells were taken from 
the peritoneal cavity of the mice. The total cells count was 
maintained up to 1 x 106
Grouping of the mice and outline of the treatment 
 after dilution and was given 
intraperitoneally. The treatment was started after seven days of 
induction of tumor cells [32, 33].  
Animals were grouped into nine groups with each group contains six 
animals. The animals of eight groups (group 2-8) received DLA cells 
(1 x 106 
Group 1 and 2 represents normal control and tumor control 
respectively.  
cells per mice), and group 1 was kept as a control group. 
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Group 3 represents positive control, (Received 5-fluorouracil 
injection at 20 mg/kg body weight, orally).  
Group 4, 5 and 6 represents treatment control, (Received 6-SRGO at 
the doses of 100 mg/kg, 200 mg/kg and 400 mg/kg body weight 
respectively orally).  
Group 7, 8 and 9 represents treatment control group, (Received 6-
SRGO-LMM at the doses of 100 mg/kg, 200 mg/kg and 400 mg/kg 
body weight respectively orally).  
Evaluation of clinical parameters 
During this study, the cancer cells were inoculated into the 
animals and the treatment for that cancer was started after 24 h 
one time a day for 14 d. Once after all the doses were finished, the 
animals were sacrificed by euthanasia. The samples of the blood 
were withdrawn from each mouse at predetermined time from 
retro-orbital plexus bleeding. Various parameters were checked 
which include, count of the cancer cells, hematological parameters 
consist of the content of Hb, RBC count, WBC count, platelet count 
and the volume of packed cells. Serum enzyme and the lipid profile 
include a count of total cholesterol (TC), triglycerides (TG), 
aspartate aminotransferase (AST), alanine aminotransferase (ALT) 
and alkaline phosphatase (ALP) and the derived parameters such 
as total lifespan (%) of the animal, body weight of the animal used 
and the cancer cell count.  
Statistical analysis 
All data are expressed as means±SEM. One way ANOVA followed by 
Dunnetts post-test was used for in vivo anticancer activity. P<0.01 
was considered as significant. Prism 5 Demo software has been used 
for the statistical analysis. 
RESULTS 
We have developed and investigated mixed micelles composed of 
phospholipids (soyalecithin S80) and SCH as an effective 
nanocarrier for the delivery of a natural lipophilic anticancer 
bioactive 6-SGL from 6-SRGO to enhance both in vitro cytotoxicity 
and in vivo anticancer activity of 6-SGL.  
Quantification of 6-SGL present in GO 
In the present study 6-SGL present in the GO was quantified by rapid 
and sensitive RP-HPLC method and the 6-SGL was quantified at a 
retention time of 10.30 min at the wavelength 281 nm (fig. 1). The 
amount of 6-SGL present in 6-SRGO was found to be 20%±2% 
whereas the optimized formulation 6-SRGO-LMM was found to have 
16%±1% when compare to the pure isolated 6-SGL. 
 
 
Fig. 1: HPLC chromatograms of pure 6-SGL (A), 6-SGL from 6SRGO (B) and 6-SGL from 6-SRGO-LMM (C) formulation 
 
Preparation and optimization of 6-SRGO-LMM by 32
6-SRGO-LMM was produced and the effect of these prepared 




The DC and EE were in the range of 78–97% and 70–89% 
respectively. A good fit (r2 for DC = 0.7656 and EE = 0.8875) was 
observed between the DC, EE and the independent variables. 
 
factorial designs [34]. The mean PS was observed in between 
300–400 nm and was affected by the selected variables (r2 = 
0.9247).  
Fourier transform infrared spectroscopy 
In the IR spectra of 6-SRGO (fig. 2A), following peaks are assigned,-
OH stretching (~3124 cm−1), Aromatic –CH stretching (~2994 
cm−1), Aliphatic–CH stretching (~2852 cm−1), -C=O stretching 
(~1736 cm−1) and OH bending out of the plan (~1373 cm−1), while 
in 6-SRGO-LMM (fig. 2C), 6-SRGO incorporated with polymer 
phospholipid, the remarkable peak of an active drug such as–C=O 
ketone stretching and–OH bending were not seen.  
Differential scanning calorimetry 
6-SRGO-LMM and 6-SRGO were analyzed by Differential scanning 
calorimetry to determine the onset, maximum temperature and 
enthalpy (table 1 and fig. 3).  
 
Table 1: Differential scanning calorimetry analysis 
 A B 
Peak ( °C) 240.65 148.26 
Onset ( °C) 223.87 135.51 
Enthalpy (J/g) 31.11 56.74 
 
Fig. 2: Fourier transform infrared (FT/IR) spectroscopy 




The obtained 6-SRGO-LMM solution appeared clear and light 
yellowish in color (fig. 4). The fig. also shows the suspension of pure 
6-SRGO dispersed in water at the same drug concentration similar to 
that reported in the literature [35]. 
Sathiyanarayanan et al. 




Fig. 3: Differential scanning calorimetry (DSC) analyses of (A) 6-
SRGO and (B) 6-SRGO-LMM 
Fig. revealed that the prepared formulation was monodispersed, 
tightly packed and spherical shaped mixed micelles whose size 
measured by laser scattering technique was correlated well with 
that by TEM. 
Evaluation of 6-SRGO-LMM stability 
Stability study reveals that 6-SRGO-LMM did not show noticeable 
changes in their size (340±15 nm) and EE (89±2.01%). The 
sedimentation of the drug was not observed during short-term 
stability studies. A drug loss of meager 3.62% was probably due to 
the partial decomposition of 6-SGL.  
This indicated that the drug-loaded micelles were physically stable 
at room temperature for at least 3 mo. 
  
 
Fig. 4: Transmission electron micrograph of optimized 6-SRGO-LMM 
 
In vitro release study 
The dialysis method is the most suitable method that simulated the 
circumstance of drug in vivo. The release pattern of 6-SGL from 6-
SRGO-LMM in comparison with 6-SGL from 6-SRGO was investigated 
in gastric fluids (pH 1.2), and intestinal fluids (pH 7.4). Fig. 5 showed 
the dissolution profile of 6-SGL from 6-SRGO-LMM and 6-SRGO in 
both HCl (pH 1.2) and phosphate buffer saline (pH 7.4), respectively. 
6-SGL release from the mixed micellar system was always slower 
than the corresponding 6-SGL from 6-SRGO escaped rapidly from 
the dialysis bag approximately 60% within 2 h and the release was 
over 95 % by 6 h. The profile of the 6-SRGO-LMM showed a very 
slow release of 6-SGL approximately 30% within 2 h and the release 
was over 95 % by 42 h. 
  
 
Fig. 5: In vitro release profiles of 6-SGL from 6-SRGO and from 6-SRGO-LMM 
 
In vitro anticancer activity 
The in vitro anticancer activity of 6SRGO-LMM was investigated and 
compared with the free drug in solution, blank mixed micelles and 
marketed Adriamycin (Doxorubicin) against human breast cancer 
MCF-7 cells using in vitro SRB assay. The results illustrated in table 
2, indicated that 6SRGO-LMM displayed better cytotoxic activity 
than the 6-SRGO and the blank mixed micelles. The total growth 
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inhibition concentration against MCF-7 was found to be 23.2 
μg/ml, 26.8 μg/ml and>80 μg/ml for 6-SRGO-LMM, 6-SRGO and 
blank respectively. LC50 against MCF-7 of 6-SRGO-LMM was>80 
μg/ml, whereas free 6-SGL from GO in solution and blank mixed 
micelles showed>80 μg/ml. The representative images are shown 
in fig. 6. 
 
Table 2: In vitro cytotoxic effect of 6-SRGO-LMM on MCF-7 breast cancer cells 
 Drug concentration (µg/ml) calculated from graph 
MCF 7 LC50 TGI GI50 
6-SRGO >80 56.4 26.8 
Blank >80 >80 >80 
6-SRGO-LMM >80 55.9 23.2 
ADR 60.8 29.5 <10 
Each point represents an average±SD (n = 3). 
 
 
Fig. 6: In vitro cytotoxicity study on the breast cancer cell line (MCF 7), (A) MCF 7 control, (B) Treatment control, (C) Treated with 6-SRGO, 
(D) treated with 6-SRGO-LMM 
 
Acute toxicity study 
No death or toxic effect on tested animals were recorded during first 
24 h as well as 14 d of observation after oral treatment of 6-SRGO 
and 6-SRGO-LMM at the doses of 55 mg/kg, 175 mg/kg, 550 mg/kg, 
1750 mg/kg and 2000 mg/kg body weight. 
In vivo anticancer activity of 6-SRGO and 6-SRGO-LMM against 
dalton’s ascitic lymphoma (DAL) in mice 
In the in vivo anticancer activity, the average lifespan of tumor 
control group of animals was found to be 48% whereas an increase 
in life span was observed up to 78%, 81% and 84% for group 
treated with 6-SRGO at the doses of 100, 200 and 400 mg/kg body 
weight and 88.5%, 89.5% and 90.5% for group treated with 6-SRGO-
LMM at the doses of 100, 200 and 400 mg/kg body weight 
respectively.  
However, in group treated with 5-FU the overall life span of the 
animals was found to be 94%, which shows the very potent 
cytotoxic nature of 5-FU [36].  
As shown in table 3, except the WBC count, all other hematological 
parameters have been decreased significantly for groups treated 
with 6-SRGO-LMM than the groups treated with 6-SRGO at all three 
doses, compared to normal control group of animals. 
 
Table 3: Effect of 6-SRGO and 6-SRGO-LMM on hematological parameters 
Treatment Total WBC cells/mlx10 Rbc count mill/cumm 3 Hb gm/dl PCV % Platelets lakhs/cumm 
G 10.35±1.30 1 4.30±1.85 12.50±1.34 14.25±2.44 3.30±0.95 
G 15.22±2.642 2.68±0.72a** 6.80±0.95a** 38.36±3.35a** 1.70±0.42a** 
G
a** 
12.32±1.303 4.05±1.40b** 11.90±1.48b** 16.40±1.40b** 2.94±0.65b** 
G
b** 
12.90±2.044 3.45±1.05b** 11.60±1.22b** 17.34±2.30b** 2.88±0.54b** 
G
b** 
13.08±2.265 3.85±1.34b** 12.35±1.66b** 18.08±2.66b** 3.04±0.68b** 
G
b** 
12.66±2.286 4.10±1.45b** 12.15±1.36b** 17.84±2.46b** 2.94±0.62b** 
G
b** 
12.34±1.557 4.06±1.72b** 12.24±1.55b** 17.38±2.40b** 3.26±0.84b** 
G
b** 
12.22±1.508 4.10±1.75b** 12.28±1.58b** 17.30±2.35b** 3.30±0.86b** 
G
b** 
11.80±1.429 4.15±1.78b** 12.35±1.62b** 17.26±2.30b** 3.35±0.88b** b** 
G1–Normal Control, G2–Cancer Control, G3–Positive control, G4 to G6-Treatment control 6-SRGO 100,200,400 mg/kg, G7 to G9–Treatment control 
(6-SRGO-LMM 100,200,400 mg/kg), All values are expressed as mean±SEM for 6 animals in each group and results were analyzed by using One way 
ANNOVA, followed by Dunnetts post test, a**Values are significantly different from normal control (G1) at P<0.01, b**Values are significantly different 
from cancer control (G2
 
) at P<0.01 
The induction of DLA cells, rises the level of cholesterol, aspartate 
aminotransferase, alanine aminotransferase and alkaline 
phosphatase to the significant level when compared to the normal 
group. The treatment with 6-SRGO-LMM recovers the above 
mentioned changes to the normal level than the groups treated with 
6-SRGO at all three doses (table 3). 
Packed cell volume, as well as viable tumor cell counts, were 
reduced in the group treated with 6-SRGO-LMM more significantly 
than the groups treated with 6-SRGO at all three doses when 
compared to tumor control groups (table 4 and 5).  
DISCUSSION 
6-SGL from ginger has been well established for its anticancer 
potential. However, its usage as a therapeutic anticancer agent is 
limited due to its poor water solubility and bioavailability. As per the 
best knowledge of authors, 6-SGL in pure form is reported to be 
unstable in simulated gastric and intestinal fluids in GI [37], thus 
expected to be unstable when administered orally. At the best of our 
knowledge, there have been no studies reported to formulate 6-SGL to 
solve the above problems. Obtaining pure compound from herbals by 
tedious isolation processes and formulating them are quite expensive, 
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moreover, single phytocompounds in most cases exhibit less 
pharmacological activities than when administer in the form of 
enriched extracts due to synergistic activity. Thus in present study, an 
attempt has been made to formulate the 6-SRGO-LMM composed of 
phospholipid (soya lecithin S80) and SCH as an effective nanocarrier 
for the delivery of a natural lipophilic anticancer bioactive 6-SGL. 
 
Table 4: Effect of 6-SRGO and 6-SRGO-LMM on serum enzymes and lipid proteins 
Treatment Cholesterol (mg/dl) TGL (mg/dl) AST (U/l) ALT (U/l) ALP (U/l) 
G 110.085±3.05 1 136.85±2.55 38.40±1.65 33.28±1.45 132.28±2.40 
G 146.95±4.342 220.28±4.40a** 78.6±2.74a** 62.32±2.60a** 265.30±4.35a** 
G
a** 
126.30±3.843 169.15±2.65b** 44.40±1.72b** 34.52±1.70b** 154.45±2.40b** 
G
b** 
123.44±3.644 172.32±2.84b** 50.15±2.82b** 40.35±2.02b** 171.85±2.90b** 
G
b** 
122.30±3.605 166.15±2.56b** 49.05±2.32b** 36.84±1.86b** 172.35±2.94b** 
G
b** 
114.20±3.526 171.80±2.76b** 46.50±2.20b** 37.35±1.94b** 167.34±2.36b** 
G
b** 
118.30±3.507 164.25±2.72b** 43.32±2.34b** 35.32±1.58b** 164.20±2.30b** 
G
b** 
116.44±3.468 163.32±2.70b** 42.35±2.34b** 34.92±1.52b** 162.16±2.22b** 
G
b** 
114.52±3.409 158.30±2.48b** 41.95±2.22b** 34.60±1.46b** 160.22±2.18b** b** 
G1–Normal Control, G2–Cancer Control, G3–Positive control, G4 to G6–Treatment control 6-SRGO 100,200,400 mg/kg, G7 to G9–Treatment control 
6-SRGO-LMM 100,200,400 mg/kg, All values are expressed as mean±SEM for 6 animals in each group and results were analyzed by using One way 
ANNOVA, followed by Dunnetts post test, a**Values are significantly different from normal control (G1) at P<0.01, b**Values are significantly different 
from cancer control (G2
 
) at P<0.01 
Table 5: Effect of 6-SRGO and 6-SRGO-LMM on the life span, body weight and cancer cell count of tumor induced mice 
Treatment Number of animals % ILS life span Increase in body weight grams Cancer cell count ml X 106 
G 6 1 >>30 d 2.22±0.68 - 
G 6 2 48% 9.44±1.86 2.75±0.80a** 
G
a** 
6 3 94% 5.66±0.42 1.30±0.22b** 
G
b** 
6 4 78% 5.98±0.84 1.66±0.50b** 
G
b** 
6 5 81% 6.05±0.88 1.38±0.23b** 
G
b** 
6 6 84% 6.18±0.94 1.54±0.36b** 
G
b** 
6 7 88.5% 5.60±0.75 1.44±0.32b** 
G
b** 
6 8 89.5% 5.58±0.70 1.40±0.26b** 
G
b** 
6 9 90.5% 5.55±0.64 1.37±0.23b** b** 
G1–Normal Control, G2–Cancer Control, G3–Positive control, G4 to G6–Treatment control 6-SRGO 100,200,400 mg/kg, G7 to G9–Treatment control 6-
SRGO-LMM 100,200,400 mg/kg, All values are expressed as mean±SEM for 6 animals in each group and results were analyzed by using One way 
ANNOVA, followed by Dunnetts post test, a**–Values are significantly different from normal control (G1) at P<0.01, b**–Values are significantly 
different from cancer control (G2
 
) at P<0.01 
A series of 6-SRGO-LMM were prepared and observed physically for 
phase separation. In the process of reformulations study, the 
concentrations of phospholipid and SCH that would give non-
coagulation and non-sedimenting mixed micelles were determined. 
A 32 factorial design was taken to optimize their concentrations. The 
concentration of 6-SRGO was kept constant. As per 32
  
factorial 
designs, nine different batches of the different concentration ratio of 
phospholipid and SCH were prepared. The responses obtained from 
these batches are shown in table 6. The data obtained was subjected 
to multiple regression analysis using design expert 10 software. 
Table 6: Regression analysis results of measured responses 
Coefficients Parameters 
Micelles size Drug content Encapsulation efficiency 
β 356.11 0 86.27 81.55 
β1 50.33   -0.47 6.22 
β 12.67 2 4.82 1.61 
β11 -   - - 
β - 22 - - 
β - 12 - -3.60 
r 0.9247 2 0.7656 0.8875 
 
The results of multiple regression analysis of the obtained data are 
summarized in table 6. The adequacy of fitted model was checked by 
analysis of variance. To study the interaction effects of the 
independent variables, response surface plots were constructed 
using Design Expert 10 software (fig. 7). 
From the factorial design study (table 6), it is observed that positive 
coefficients of the main term X1 and the interaction term X1X1 
indicated a favorable effect on the mean micelle size, with the 
phospholipid chiefly influencing than SCH. The phospholipid had a 
linear effect on the mean micelles size as seen in surface plot (fig. 
7A). Smaller micelles were obtained at low phospholipid content, 
probably due to high distribution efficiency of an internal phase into 
external phase [3]. Increase in the viscosity of internal phase with an 
increased amount of phospholipid also provides resistance for mass 
transfer during diffusion of an internal phase into the external phase 
leading to micelles enlargement. The increase in the mean micelles 
size may also be due to the hydrophobic-hydrophobic interaction of 
phospholipid with the drug.  
Both X1 and X2 showed favorable positive effects on DC and EE. In 
case of phospholipid, it showed the linear effect on DC and EE. 
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Further more in case of SCH it also showed linear effects on DC and 
EE. As seen in surface plot (fig. 7B, C), the phospholipid favored DC 
and EE by hydrophobic-hydrophobic interactions with drugs leading 
to the formation of interpenetrated network chain. However, SCH 




Fig. 7: Response surface plot illustrating effect of factorial variables. (A) Particle size, (B) Encapsulation efficiency, (C) drug content 
 
Based on the results of the factorial design, batch F5 6-SRGO-LMM 
having acceptable PS, DC and EE was selected as an optimized batch. 
The size of the optimized 6-SRGO-LMM was 380±3 nm–which was 
not significantly different from its blank counterpart. Large 
molecules of more than 40 kDa in size and certain particles ranging 
from 10 to 400 nm can leave the vascular bed and accumulate inside 
the interstitial space of the tumor (EPR effect) [24]. Drug delivery to 
specific sites of the body is influenced by the size of the mixed 
micelles; smaller micelles may tend to minimize the particle uptake 
by nontargeted cells, including their premature clearance by the 
mononuclear phagocytic system [38]. It is hypothesized that mixed 
micelles developed in the present study are of appropriate size to be 
able to passively target the tumor site. 
In the IR spectra of 6-SRGO-LMM does not shows a remarkable peak 
of an active drug such as–C=O ketone stretching and–OH bending, 
thus final IR spectra of 6-SRGO-LMM revealed that 6-SRGO has been 
completely encapsulated with phospholipid in the formulation. 
According to the DSC results, the melting point of free 6-SRGO was 
observed at around 240 °C with the enthalpy 31.11 J/g. In case of 6-
SRGO-LMM thermogram, the free 6-SRGO peak was disappeared and 
shifted to 148 °C indicating molecular dispersion of 6-SRGO inside 
mixed micelles. Thermograms of 6-SRGO-LMM show a sharp 
endothermic peak starting near about at 135 °C and ending at 155 
°C. Onset temperature at approximately 135 °C and melting point 
around 148.26 °C are desirable for particle stability at room or lower 
temperatures and digestibility in the gastrointestinal tract, 
respectively, acting as a trigger to release the active core during the 
digestion process [39]. 
The TEM image shows that there is no drug crystallization appears 
in the micellar formulations and the surface of the micelles are 
smooth and they are suspended uniformly in the formulation. The 
bright region may represent the hydrophilic shell, while the dark 
region was likely the hydrophobic core of the micelles. 
The enhanced in vitro cytotoxic activity of 6-SRGO-LMM may be 
attributed to greater cellular uptake of micelles via phagocytosis or 
the fusion process of phospholipid micelles as compare to 6-SRGO 
[40]. Therefore, 6-SRGO-LMM might have served as a potential 
nanocarrier to improve the in vitro cytotoxic activity of 6-SGL. The 
lower anticancer activity of 6-SRGO and blank mixed micelles may 
be due to their efflux by P-glycoprotein pumps. The above GI50 and 
LC50 values reveal that the 6-SRGO-LMM gives potential anticancer 
activity as compared to 6-SRGO. 
Acute toxicity study showed that oral administration of 6-SRGO and 
6-SRGO-LMM in acute dose up to 2000 mg/kg body weight did not 
produce any sign of toxicity or death in mice, suggesting a lethal 
dose 50 % (LD50) above 2000 mg/kg. An acute toxic study provides 
a guideline for selecting doses for in vivo study (1/10th and 1/20th 
of maximum dose in mice) which may be more clinically relevant 
[41]. Thus, derived doses of 100 mg/kg, 200 mg/kg and 400 mg/kg 
for both 6-SRGO and 6-SRGO-LLPS have been selected. 
In DLA tumor, a rise in ascitic tumor volume was noticed. Ascitic 
fluid gives rise to a direct nutritional source for tumor cells and a 
sudden rise in an ascitic fluid with tumor growth to meet the 
nutritional requirement of tumor cells [36]. Treatment with 6-SRGO-
LMM increased the life span of the mice, controlled the tumor 
volume and reduced the cell count of the tumor more significantly 
than the groups treated with 6-SRGO at a dose of at all three doses. 
The lifespan of the animal after starting the treatment for the cancer 
is the most reliable criteria to find out the efficacy of the drug used 
to treat the cancer [42].  
Usually, the major problem in the treatment of the cancer is the 
suppression of myeloma and the anemia [43, 44]. The anemia arises 
mainly because of reduction in the RBC count or reduction in the 
total hemoglobin count [45]. Treatment with 6-SRGO and 6-SRGO-
LMM at all three doses brought backs all the hematological 
parameters to the normal level significantly. 
Thus the results show that the 6-SRGO-LMM exhibited better 
antitumor activity against DLA bearing mice as compare to the 6-
SRGO at all three doses. 
CONCLUSION 
We have developed and investigated mixed micelles composed of 
phospholipids (soya lecithin S80) and SCH as an effective 
nanocarrier for the delivery of a natural lipophilic anticancer 
bioactive 6-SGL from 6-SRGO. The developed 6-SRGO-LMM 
exhibited higher DC and sustained release of 6-SGL from 6-SRGO. 
Micellar encapsulation of 6-SRGO resulted in remarkable stability 
for up to 90 d. Moreover, the 6-SRGO-LMM demonstrated higher in 
vitro cytotoxic activity in human breast cancer MCF-7 cells and in 
vivo anticancer activity in DAL cells than 6-SRGO, which may bring 
about reduction in dose as well as cost. As a result, this 6-SRGO-LMM 
may be used to add value to new products by increasing anticancer 
activity, in which 6-SRGO play an important role on the attenuation 
of complications associated to cancer. 
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